BioSpace News Archive

STRM.BIO today announced the appointment of Minnie Mildwoff, to its Board of Directors.

ZyVersa Therapeutics, Inc. announced today the pricing of a “reasonable best efforts” public offering of 12,727,273 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 12,727,273 shares of common stock.

Nectero Medical today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study) to evaluate the safety and efficacy of the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) in patients with infrarenal abdominal aortic aneurysms (AAAs), maximum diameter 3.5 – 5.0cm.

Johnson & Johnson announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. through an exchange offer.

Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) announces that it is presenting results of its Quality Assessment Products (“QAPs™”) for supporting the clinical use and accuracy of multiplex tests for four of the most prevalent sexually-transmitted infections (“STIs”) at the American Association of Clinical Chemistry (“AACC”) conference taking place in Anaheim, California July 23 to 27, 2023.

AEON Biopharma, Inc. announced the closing of its previously announced business combination with Priveterra Acquisition Corp., a special purpose acquisition company.

Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.

Acurx Pharmaceuticals, Inc. announced today that the Company will discuss its second quarter 2023 financial results on Monday, August 14, 2023, at 8:00 am ET before the U.S. financial markets open.

Orthogon Therapeutics LLC today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a pivotal technical milestone that has unlocked an additional $3M from its dedicated syndicate of healthcare investors.

Crescendo Biologics Ltd today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.